Drug Profile
Clostridium novyi-NT - BioMed Valley Discoveries
Alternative Names: BVD-550; BVD-CNV; BVD-CNV/IT; BVD-CNV/IV; C.novyi-NT; Clostridium novyi-NT spores; Clostridium-novyi-non-toxic; CNV-NTLatest Information Update: 24 May 2023
Price :
$50
*
At a glance
- Originator BioMed Valley Discoveries; Johns Hopkins University
- Developer BioMed Valley Discoveries; M. D. Anderson Cancer Center; Merck Sharp & Dohme
- Class Antineoplastics; Bacteria
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 Apr 2023 Clostridium novyi-NT is still in phase I trials for solid tumours in USA
- 14 Apr 2023 Efficacy and adverse events data from a phase I trial in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 14 Apr 2023 BioMed Valley Discoveries plans a phase II trial for Solid tumours